<DOC>
	<DOCNO>NCT00337649</DOCNO>
	<brief_summary>This single arm study determine efficacy safety epothilone D Herceptin combination regimen patient HER-2 positive locally advanced metastatic breast cancer . Epothilone D administer intravenously day 1 , 8 15 every 4 week dose exceed 100mg/m2 . Herceptin administer intravenously weekly schedule ; 4mg/kg load dose follow weekly maintenance dose 2mg/kg . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Epothilone D Combination With Herceptin ( Trastuzumab ) Patients With HER-2 Positive Advanced Metastatic Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>woman &gt; =18 year ; locally advance metastatic breast cancer ; HER2 overexpression ( FISH + IHC 3+ ) ; &gt; =1 measurable lesion ; one prior anthracyclinebased chemotherapy regimen metastatic setting . preexist neuropathy &gt; =grade 2 ; know CNS metastasis ; congestive heart failure , myocardial infarction within last 6 month ; previous malignancy last 5 year , except cure basal cell cancer skin , cancer situ cervix .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>